GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Travere Therapeutics Inc (NAS:TVTX) » Definitions » Shiller PE Ratio

Travere Therapeutics (Travere Therapeutics) Shiller PE Ratio : (As of Apr. 29, 2024)


View and export this data going back to 2003. Start your Free Trial

What is Travere Therapeutics Shiller PE Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Travere Therapeutics Shiller PE Ratio Historical Data

The historical data trend for Travere Therapeutics's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Travere Therapeutics Shiller PE Ratio Chart

Travere Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Travere Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Travere Therapeutics's Shiller PE Ratio

For the Biotechnology subindustry, Travere Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Travere Therapeutics's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Travere Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Travere Therapeutics's Shiller PE Ratio falls into.



Travere Therapeutics Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Travere Therapeutics's E10 for the quarter that ended in Dec. 2023 is calculated as:

For example, Travere Therapeutics's adjusted earnings per share data for the three months ended in Dec. 2023 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=-1.18/129.4194*129.4194
=-1.180

Current CPI (Dec. 2023) = 129.4194.

Travere Therapeutics Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201403 -3.250 99.695 -4.219
201406 -0.770 100.560 -0.991
201409 -0.840 100.428 -1.082
201412 -1.180 99.070 -1.541
201503 1.320 99.621 1.715
201506 -0.730 100.684 -0.938
201509 1.780 100.392 2.295
201512 -0.140 99.792 -0.182
201603 -0.080 100.470 -0.103
201606 -0.370 101.688 -0.471
201609 -1.000 101.861 -1.271
201612 -0.220 101.863 -0.280
201703 -0.320 102.862 -0.403
201706 -0.340 103.349 -0.426
201709 -0.460 104.136 -0.572
201712 -0.550 104.011 -0.684
201803 -0.460 105.290 -0.565
201806 -0.560 106.317 -0.682
201809 -1.340 106.507 -1.628
201812 -0.180 105.998 -0.220
201903 -0.990 107.251 -1.195
201906 -0.920 108.070 -1.102
201909 -0.850 108.329 -1.015
201912 -0.700 108.420 -0.836
202003 0.020 108.902 0.024
202006 -0.580 108.767 -0.690
202009 -0.440 109.815 -0.519
202012 -2.370 109.897 -2.791
202103 -0.960 111.754 -1.112
202106 -0.640 114.631 -0.723
202109 -0.590 115.734 -0.660
202112 -0.840 117.630 -0.924
202203 -1.200 121.301 -1.280
202206 -1.050 125.017 -1.087
202209 -1.090 125.227 -1.126
202212 -1.030 125.222 -1.065
202303 -1.270 127.348 -1.291
202306 -1.130 128.729 -1.136
202309 1.970 129.860 1.963
202312 -1.180 129.419 -1.180

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Travere Therapeutics  (NAS:TVTX) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Travere Therapeutics Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Travere Therapeutics's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Travere Therapeutics (Travere Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
3611 Valley Centre Drive, Suite 300, San Diego, CA, USA, 92130
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN) - rare kidney disorders that often cause end-stage kidney disease.
Executives
Jula Inrig officer: Chief Medical Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Peter Heerma officer: Chief Commercial Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
William E. Rote officer: Senior Vice President, R&D C/O RETROPHIN, INC., 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Christopher R. Cline officer: Chief Financial Officer C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, STE 300, SAN DIEGO CA 92130
Eric M Dube director, officer: Chief Executive Officer 3721 VALLEY CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92130
Elizabeth E Reed officer: SVP, GC & Corporate Secretary 9050 CAMINO SANTA FE, SAN DIEGO CA 92121
Sandra Calvin officer: VP, Corp Controller and CAO 3611 VALLEY CENTER DRIVE, SUITE 300, SAN DIEGO CA 92130
Laura Clague officer: Chief Financial Officer 370 PARK RANCH PLACE, ESCONDIDO CA 92025
Steve Aselage director 6300 DUMBARTON CIRCLE, FREMONT CA 94555
Brinkley Ruth Williams director C/O TRAVERE THERAPEUTICS, INC., 3611 VALLEY CENTRE DRIVE, SUITE 300, SAN DIEGO CA 92130
Noah L. Rosenberg officer: Chief Medical Officer C/O ESPERION THERAPEUTICS, INC., 46701 COMMERCE CENTER DRIVE, PLYMOUTH MI 48170
Suzanne Louise Bruhn director C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, SUITE 250, AUSTIN TX 78746
Neil F. Mcfarlane officer: Chief Operating Officer C/O RETROPHIN, INC., 12255 EL CAMINO REAL, SUITE 250, SAN DIEGO CA 92130
Sandra Poole director 830 WINTER STREET, WALTHAM MA 02451
Ron Squarer director C/O ADC THERAPEUTICS SA, BIOPOLE, ROUTE DE LA CORNICHE 3B, EPALINGES V8 1066

Travere Therapeutics (Travere Therapeutics) Headlines

From GuruFocus